宫颈癌阴道剂量点与阴道狭窄的剂量-效应关系:EMBRACE-I 子研究
该研究纳入 EMBRACE-I 研究中 6 个中心的 301 例局部晚期宫颈癌患者,评估阴道剂量点与阴道狭窄的剂量-效应关系。中位随访 49 个月,G2 及以上阴道狭窄发生率为 20%(59 例)和 3%(8 例)分别为 G2 和 G3。PIBS、PIBS+2 cm 和 RV-RP 点剂量较高与 G2 及以上阴道狭窄风险增加显著相关。
要点
- 301 例患者中,G2 和 G3 阴道狭窄发生率分别为 20%(59 例)和 3%(8 例)。
- PIBS、PIBS+2 cm 和 RV-RP 点剂量较高与 G2 及以上阴道狭窄风险增加显著相关。
- 诊断时阴道受累、年龄较高、VRL 较短和使用 tandem-ovoid 施源器也是阴道狭窄的危险因素。
核心结论
- PIBS+2 cm、PIBS 和 RV-RP 剂量点剂量较高与 G2 及以上阴道狭窄相关。
研究设计与样本
- 研究纳入 EMBRACE-I 研究中 6 个中心的 301 例接受放化疗和图像引导自适应近距离放疗的局部晚期宫颈癌患者。
- 从治疗计划系统获取阴道剂量点(包括 PIBS 点和 RV-RP 点)剂量信息,并评估阴道参考长度(VRL)。
- 阴道狭窄按 CTCAEv3.0 系统在基线和随访时前瞻性评估,主要终点为 G2 及以上阴道狭窄。
- 采用 Cox 比例风险回归模型评估阴道剂量点剂量、VRL、年龄、阴道受累和施源器对 G2 及以上阴道狭窄的影响。
主要发现
- 中位随访 49 个月,G0、G1、G2 和 G3 阴道狭窄发生率分别为 25%(76 例)、52%(158 例)、20%(59 例)和 3%(8 例)。
- PIBS+2 cm、PIBS、PIBS-2 cm 和 RV-RP 的中位总剂量分别为 52.9(IQR 49.3-64.7)、41.0(IQR 15.4-49.0)、4.1(IQR 2.9-7.0)和 64.6(IQR 60.0-70.6)Gy EQD23。
- PIBS、PIBS+2 cm 和 RV-RP 点剂量较高与 G2 及以上阴道狭窄风险增加显著相关。
- 其他危险因素包括诊断时阴道受累、年龄较高、VRL 较短和使用 tandem-ovoid 施源器。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To evaluate dose-effect relationships between vaginal dose points and vaginal stenosis in patients treated for locally advanced cervical cancer with radio(chemo)therapy and image-guided adaptive brachytherapy. MATERIAL AND METHODS: Patients from six centres participating in the EMBRACE-I study were included. Information on doses to different vaginal dose points, including the Posterior-Inferior Border of Symphysis (PIBS) points and recto-vaginal reference (RV-RP) point, were retrieved from the treatment planning system. In addition, the vaginal reference length (VRL) was evaluated. Vaginal stenosis was prospectively assessed according to the CTCAEv3.0 system at baseline and follow-up. Primary endpoint was grade 2 or higher (G ≥ 2) vaginal stenosis. Impact of dose to the vaginal dose points, and impact of VRL, age, vaginal involvement and applicator on vaginal stenosis G ≥ 2 was evaluated with a Cox proportional-hazard regression model. RESULTS: 301 patients were included. Median follow-up was 49 months. During follow-up, the incidence of G0, G1, G2, and G3 vaginal stenosis was 25% (76), 52% (158), 20% (59) and 3% (8), respectively. Median total doses to PIBS+2 cm, PIBS, PIBS-2 cm and the RV-RP were 52.9 (IQR 49.3-64.7), 41.0 (IQR 15.4-49.0), 4.1 (IQR 2.9-7.0) and 64.6 (IQR 60.0-70.6) Gy EQD23, respectively. Higher doses to the PIBS, PIBS + 2 cm and RV-RP points were significantly associated with increased risk for vaginal stenosis G ≥ 2. Other risk factors for vaginal stenosis were: vaginal involvement at diagnosis, higher age, shorter VRL and use of a tandem-ovoid applicator. CONCLUSION: Higher doses to the PIBS+2 cm, PIBS and RV-RP dose points are associated with vaginal stenosis G ≥ 2.
引用
- Westerveld H, Kirchheiner K, Nout RA, et al. Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer: An EMBRACE-I sub-study. Radiother Oncol. 2022. PMID: 35063582. doi:10.1016/j.radonc.2021.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。